Russell Investments Group’s Soleno Therapeutics SLNO Stock Holding History

Russell Investments Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-58,692	Closed	-$1.97M	–	4505
2026 Q1	$1.97M	Buy	58,692 +12,014	+26%	+$471K	﹤0.01%	1892
2025 Q4	$2.16M	Sell	46,678 -47,665	-51%	-$2.61M	﹤0.01%	1823
2025 Q3	$6.38M	Buy	94,343 +11,390	+14%	+$844K	0.01%	1162
2025 Q2	$6.95M	Buy	82,953 +82,932	+394,914%	+$6.21M	0.01%	1023
2025 Q1	$1.5K	Buy	+21	New	+$1.02K	﹤0.01%	3555
2024 Q4	–	Sell	-11	Closed	-$555	–	3782
2024 Q3	$555	Buy	+11	New	+$527	﹤0.01%	3561
2021 Q2	–	Sell	-11,613	Closed	-$219K	–	3287
2021 Q1	$219K	Buy	+11,613	New	+$374K	﹤0.01%	2797

Russell Investments Group's SLNO Position: Q2 2026 in Review

Russell Investments Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 58,692 shares — an estimated $1.97M sold.

Russell Investments Group first reported a position in SLNO in Q1 2021 and held it in 7 quarters. The position peaked at $6.95M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Russell Investments Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Russell Investments Group sold 58,692 Soleno Therapeutics shares in Q2 2026, an estimated $1.97M.
Russell Investments Group first reported a position in Soleno Therapeutics in Q1 2021 and held it in 7 quarters.
Russell Investments Group's Soleno Therapeutics position peaked at $6.95M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.